Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice

about

Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours.

P2860

Q34141825-A2464B6E-3119-43A9-9DEF-8B6D5F13166E

P2860

Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice

Item

http://www.wikidata.org/entity/Q56979972

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в грудні 2012

@uk

name

Chronic therapy in gastrointes ...... ap between theory and practice

@en

Chronic therapy in gastrointestinal stromal tumours

@nl

type

Item

label

Chronic therapy in gastrointes ...... ap between theory and practice

@en

Chronic therapy in gastrointestinal stromal tumours

@nl

prefLabel

Chronic therapy in gastrointes ...... ap between theory and practice

@en

Chronic therapy in gastrointestinal stromal tumours

@nl

P1476

Chronic therapy in gastrointes ...... ap between theory and practice

@en

P2093

Guido Biasco

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study.

An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes

Clinical management of gastrointestinal stromal tumors: before and after STI-571.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Imatinib: a selective tyrosine kinase inhibitor.

Improving adherence to antiretroviral therapy for youth living with HIV/AIDS: a pilot study using personalized, interactive, daily text message reminders.

Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

P2888

s11523-012-0221-1

P304

243-246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-012-0221-1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Margherita Nannini

Maria A Pantaleo

Maristella Saponara

P577

2012-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22592950

http://www.w3.org/2001/XMLSchema#string

Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice

about

P2860

P2860

Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698